Thomas H Sisson MD
Critical Care Medicine, Pleural Disease
Associate Professor
Join to view full profile
1500 East Medical Center Dr3RD floor Taubman CTR Recp CAnn Arbor, MI 48109
Phone+1 734-647-9342
Fax+1 734-615-5348
Dr. Sisson is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MichiganFellowship, Pulmonary Disease and Critical Care Medicine, 1995 - 1998- University of MichiganResidency, Internal Medicine, 1992 - 1995
University of Michigan Medical SchoolClass of 1992
Certifications & Licensure
MI State Medical License 1997 - 2028
American Board of Internal Medicine Critical Care Medicine- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Outgoing Public Health Reporting from EpicCare Functionality, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- A potent inhibitor of PAI-1, MDI-2517, mitigates disease severity in a preclinical systemic sclerosis model.Enming J Su, Pei-Suen Tsou, Mark Warnock, Natalya Subbotina, Kris Mann
JCI Insight. 2026-04-08 - 4 citationsDegradation of oxidized phospholipids by lysosomal phospholipase A2 regulates pulmonary fibrosis.Doyun Kwak, Song Ling, Natalya Subbotina, James A Shayman, Tomas H Sisson
American Journal of Physiology. Lung Cellular and Molecular Physiology. 2025-08-01 - 2 citationsPAI-1 interaction with sortilin-related receptor 1 is required for lung fibrosis.Thomas H Sisson, John J Osterholzer, Lisa Leung, Venkatesha Basrur, Alexey Nesvizhskii
JCI Insight. 2025-06-09
Other
- Cystic fibrosis: Investigational therapiesSisson TH, Simon RH
http://www.uptodate.com/contents/cystic-fibrosis-investigational-therapies
UpToDate, Wolters Kluwer Health - 2012-06-22
Grant Support
- A Novel PAI-1 Function Drives Lung FibrosisUNIVERSITY OF MICHIGAN AT ANN ARBOR2022–2026
- Oxidized Phospholipids Derived from Apoptotic Pneumocytes Drives Macrophage Activation and Initiates Lung FibrosisUNIVERSITY OF MICHIGAN AT ANN ARBOR2021–2025
- The Anti-Protease And Vitronectin-Binding Functions Of PAI-1 In Lung FibrosisNational Heart, Lung, And Blood Institute2007–2011
- Plasmin, Fibrin, And Metalloproteinases In Lung FibrosisNational Heart, Lung, And Blood Institute2000–2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
